Ads
related to: severe asthma exacerbation- Sign Up
Register Or Activate Your Card—
Find Out If You're Eligible Today.
- Dosing And Administration
Info On How To Self Administer
Find Additional Support On The Site
- Home
Official Patient Website—
Get Treatment Info Today.
- Register For A Webinar
Learn From Medical Professionals
Hear From Real Patients Like You
- Treatment Support
Discover Educational Resources
& Get Financial Support Information
- Read Patient Stories
Hear Stories From Ambassadors
Learn More On The Official Site
- Sign Up
Search results
GSK's Experimental Asthma Drug Reduces Severe Attacks, Phase 3 Trial Data Shows
Benzinga via Yahoo Finance· 2 days agoTuesday, GSK plc (NYSE:GSK) released headline results from the phase III clinical trials SWIFT-1 and...
GSK Studies on Depemokimab for Severe Asthma Meet Primary Goals
Zacks via Yahoo Finance· 1 day agoType II inflammation is typically identified by elevated levels of eosinophils (a type of white...
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
Zacks via Yahoo Finance· 9 hours agoSWIFT-1 and SWIFT-2 were replicate 52-week, randomized, double-blind...receive depemokimab or a...
Amgen/AstraZeneca Say Asthma Drug Shows Activity In Another Lung Disease Across Broad Patient...
Benzinga via Yahoo Finance· 3 days agoThe primary results showed that treatment with Tezspire led to a 17% numerical reduction in the...
First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential
Benzinga via Yahoo Finance· 1 day agoWednesday, Sanofi SA (NASDAQ:SNY) reported results from the Phase 2 study of oral rilzabrutinib in...
Research finds few moderate or severe asthma patients prescribed recommended inhaler regimen
Medical Xpress· 2 days agoIn the United States, ICS-formoterol inhalers include Symbicort (budesonide-formoterol) and Dulera...
GSK boasts win for depemokimab in asthma trials
Clinical Trials Arena via Yahoo Finance· 3 days agoThe pharma giant announced the drug met primary endpoints in both the SWIFT-1 (NCT04719832) and SWIFT-2 (NCT4718103) trials of a reduction in ...
GSK Experimental Drug Reduces Severe Asthma Attacks in Key Trial
Bloomberg· 3 days agoAn experimental drug from GSK Plc reduced asthma attacks in late-stage trials, paving the way for a...
NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD
FOX 4 Kansas City· 4 days agoThe primary results showed that treatment with Tezspire led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared ...
Tezepelumab Shows Potential for COPD, Negative Trial Notwithstanding
MedPage Today· 2 days agoAsthma drug may benefit patients with blood eosinophil counts indicative of type 2 inflammation
Ad
related to: severe asthma exacerbation
